We developed automated homogeneous immunoassays, based on immunolysis of liposomes, for measuring phenytoin, phenobarbital, and carbamazepine from serum. Liposome lysis was detected spectrophotometrically from entrapped giucose-6-phosphate dehydrogenase activity. The procedure was fully automated on a routine automated clinical analyzer. Within-run, between-run, dilution, and recovery tests showed good accuracies and reproducibilities. Bilirubin, hemoglobin, triglycerides, and Intra- 
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Several kinds of immunoassays involving liposomes have been investigated

Results
Liposome preparation.
We examined the reproducibility of liposome preparations, measuring liposome enzyme content after treatment with detergent (Triton X-l00, 1 g/L). The enzyme contents of five liposome preparations sensitized to PHT, PB, and CBZ were 18.8 (SD 1.35), 18.4 (SD 1.38), and 18.2 (SD 1.11) Figure 2 shows standard curves for PHT, PB, and CBZ liposome inununoassays. These competitive assays covered the PHT, PB, and CBZ therapeutic ranges (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , and 4-12 mg/L, respectively). Reagents were stable at 10 #{176}C for 1 week, and we calibrated the assays daily.
Precision of the assay. We added three different concentrations of each drug to drug-free serum samples. By replicate analysis of these samples, we assessed both within-run and between-run precisions. For the PHT, PB, and CBZ assays, within-nm CVs varied from 1.3% to 2.1%, from 0.7% to 1.6%, and from 1.0% to 1.2%, respectively. Between-run CVs varied from 2.9% to Each point represents the mean absorbance ± SD of five Imposomepreparations 5.5%, from 1.2% to 3.2%, and from 1.6% to 5.1%, respectively (Table 1) . Two human serum samples, to which each drug was added, were diluted serially with saline and subjected to liposome immunoassays for PHT, PB, and CBZ. Linear serum-dilution curves were obtained (Figure 3) . (Table 2 ). For examination of emdogenous complement activity in the sera, heat-treated (56 #{176}C, 30 miii) sera containing each drug were tested. Measured drug concentrations in intact sera were identical to that of the heat-treated sera. Endogemous complement activity had no effect on these assays (data not shown).
We examined the PHT, PB, and CBZ assay specificities by adding related drugs (Table 3) . We found no significant interferences with any compound tested.
Accuracy. We evaluated analytical recoveries of each drug from spiked samples ( Table 4) . Recoveries of PifF, PB, and CBZ ranged from 90.0% to 98.0%, from 96.0% to 101.0%, and from 98.8% to 103.8%, respectively.
Correlation.
We compared our liposome lysis assay with the EMIT and the TDx methods (Figure 4) . The Dilution
FIg.3. Dilutiontests
Each drug was added to two serum samples, which weredilutedseriallywith saline and assayed By using these liposome-lysis automated assays for PHT, PB, and CBZ, we rapidly obtained accurate and reproducible results for therapeutic drug monitoring.
